21
Large caps: Halvorsen Pharma falls 11% after a late-stage trial misses
The trial summary is two pages and more balanced than the headlines.
Halvorsen (HLVP) reported that its heart-failure drug missed its primary endpoint. Secondary endpoints showed some benefit. It is the week's largest large-cap decliner.
Read it at the source
Cascadic Analysis 1
Investment ImpactPipeline depth matters more than one trial
Where to jump in, or out? (Not financial advice.)
Halvorsen has four other late-stage programs. The market may be pricing this as if it had one.
Confidence: Low
9
Rabbit Holes
-
Primary vs secondary endpoints, explainedWhy a "miss" can still mean something. · Fernbank Review of Medicine · Swim · 30 min1